Loading…

Sex Hormone Receptor Repertoire in Breast Cancer

Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions us...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Breast Cancer 2013-01, Vol.2013 (2013), p.50-63
Main Authors: Higa, Gerald M., Fell, Ryan G.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3
cites cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3
container_end_page 63
container_issue 2013
container_start_page 50
container_title International Journal of Breast Cancer
container_volume 2013
creator Higa, Gerald M.
Fell, Ryan G.
description Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.
doi_str_mv 10.1155/2013/284036
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e688a76f271245858af3adaf90674919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373578717</galeid><airiti_id>P20151207002_201312_201708020006_201708020006_50_63</airiti_id><doaj_id>oai_doaj_org_article_e688a76f271245858af3adaf90674919</doaj_id><sourcerecordid>A373578717</sourcerecordid><originalsourceid>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</originalsourceid><addsrcrecordid>eNqFkttrFDEUhwdRbKl98llZEESUbXO_vAh1UVspKF6ewzFzsptldrJNZr3892Z36tIFwcxDMjnf-chMfk3zmJIzSqU8Z4Tyc2YE4epec8yIJVNOjb2_X2ty1JyWsiR1SMq50g-bIyY4E8aK44Z8wV-Ty5RXqcfJZ_S4HlKuizXmIcWMk9hP3mSEMkxm0HvMj5oHAbqCp7fzSfPt3duvs8vp9cf3V7OL6ylIa4dpsEEQT6linHpgsmXcKxnAMgg0UPCtUQEFcquV9chQES_RsBYkaqOAnzRXo7dNsHTrHFeQf7sE0e02Up47yEP0HTpUxoBWgWnKhDTSQODQQrBEaWGpra7Xo2u9-b7C1mM_ZOgOpIeVPi7cPP1w3AgpiKyCF7eCnG42WAa3isVj10GPaVMcrRSllGtT0WcjOod6tNiHVI1-i7sLrrnURlNdqbN_UPVpcRV9vYsQ6_5Bw_M7DQuEbliU1G2GmPpyCL4aQZ9TKRnD_jMpcdvIuG1k3BiZSj-9-2f27N-AVODlCCxi38LP-B_bkxHGimCAPSwUYWJb_zDWIeY4RLdMm9zXELlP1SIpI5oQtjPS3aSJIazmVh2-SOIU538Aaubh3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540111378</pqid></control><display><type>article</type><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><source>Wiley Open Access</source><source>PubMed Central</source><creator>Higa, Gerald M. ; Fell, Ryan G.</creator><contributor>Ejlertsen, Bent</contributor><creatorcontrib>Higa, Gerald M. ; Fell, Ryan G. ; Ejlertsen, Bent</creatorcontrib><description>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</description><identifier>ISSN: 2090-3170</identifier><identifier>ISSN: 2090-3189</identifier><identifier>EISSN: 2090-3189</identifier><identifier>DOI: 10.1155/2013/284036</identifier><identifier>PMID: 24324894</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Analysis ; Breast cancer ; Hormones, Sex ; Physiological aspects ; Review</subject><ispartof>International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.50-63</ispartof><rights>Copyright © 2013 Gerald M. Higa and Ryan G. Fell.</rights><rights>COPYRIGHT 2013 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2013 G. M. Higa and R. G. Fell. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</citedby><cites>FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</cites><orcidid>0000-0001-7919-1468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845405/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845405/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24324894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ejlertsen, Bent</contributor><creatorcontrib>Higa, Gerald M.</creatorcontrib><creatorcontrib>Fell, Ryan G.</creatorcontrib><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><title>International Journal of Breast Cancer</title><addtitle>Int J Breast Cancer</addtitle><description>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</description><subject>Analysis</subject><subject>Breast cancer</subject><subject>Hormones, Sex</subject><subject>Physiological aspects</subject><subject>Review</subject><issn>2090-3170</issn><issn>2090-3189</issn><issn>2090-3189</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFkttrFDEUhwdRbKl98llZEESUbXO_vAh1UVspKF6ewzFzsptldrJNZr3892Z36tIFwcxDMjnf-chMfk3zmJIzSqU8Z4Tyc2YE4epec8yIJVNOjb2_X2ty1JyWsiR1SMq50g-bIyY4E8aK44Z8wV-Ty5RXqcfJZ_S4HlKuizXmIcWMk9hP3mSEMkxm0HvMj5oHAbqCp7fzSfPt3duvs8vp9cf3V7OL6ylIa4dpsEEQT6linHpgsmXcKxnAMgg0UPCtUQEFcquV9chQES_RsBYkaqOAnzRXo7dNsHTrHFeQf7sE0e02Up47yEP0HTpUxoBWgWnKhDTSQODQQrBEaWGpra7Xo2u9-b7C1mM_ZOgOpIeVPi7cPP1w3AgpiKyCF7eCnG42WAa3isVj10GPaVMcrRSllGtT0WcjOod6tNiHVI1-i7sLrrnURlNdqbN_UPVpcRV9vYsQ6_5Bw_M7DQuEbliU1G2GmPpyCL4aQZ9TKRnD_jMpcdvIuG1k3BiZSj-9-2f27N-AVODlCCxi38LP-B_bkxHGimCAPSwUYWJb_zDWIeY4RLdMm9zXELlP1SIpI5oQtjPS3aSJIazmVh2-SOIU538Aaubh3A</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Higa, Gerald M.</creator><creator>Fell, Ryan G.</creator><general>Hindawi Limiteds</general><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AFFIF</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7919-1468</orcidid></search><sort><creationdate>20130101</creationdate><title>Sex Hormone Receptor Repertoire in Breast Cancer</title><author>Higa, Gerald M. ; Fell, Ryan G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Breast cancer</topic><topic>Hormones, Sex</topic><topic>Physiological aspects</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Higa, Gerald M.</creatorcontrib><creatorcontrib>Fell, Ryan G.</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة دراسات المرأة - e-Marefa Women Studies</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International Journal of Breast Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Higa, Gerald M.</au><au>Fell, Ryan G.</au><au>Ejlertsen, Bent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sex Hormone Receptor Repertoire in Breast Cancer</atitle><jtitle>International Journal of Breast Cancer</jtitle><addtitle>Int J Breast Cancer</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>50</spage><epage>63</epage><pages>50-63</pages><issn>2090-3170</issn><issn>2090-3189</issn><eissn>2090-3189</eissn><abstract>Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanistic mode of action for all hormonal interventions used in treating this disease. Whereas ERα is widely accepted as the single most important predictive factor (for response to endocrine therapy), the presence of the receptor in tumor cells is also of prognostic value. Even though the clinical relevance of the two other sex hormone receptors, namely, ERβ and the androgen receptor remains unclear, two discordant phenomena observed in hormone-dependent breast cancers could be causally related to ERβ-mediated effects and androgenic actions. Nonetheless, our understanding of regulatory molecules and resistance mechanisms remains incomplete, further compromising our ability to develop novel therapeutic strategies that could improve disease outcomes. This review focuses on the receptor-mediated actions of the sex hormones in breast cancer.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>24324894</pmid><doi>10.1155/2013/284036</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7919-1468</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-3170
ispartof International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.50-63
issn 2090-3170
2090-3189
2090-3189
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e688a76f271245858af3adaf90674919
source Wiley Open Access; PubMed Central
subjects Analysis
Breast cancer
Hormones, Sex
Physiological aspects
Review
title Sex Hormone Receptor Repertoire in Breast Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A40%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sex%20Hormone%20Receptor%20Repertoire%20in%20Breast%20Cancer&rft.jtitle=International%20Journal%20of%20Breast%20Cancer&rft.au=Higa,%20Gerald%20M.&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=50&rft.epage=63&rft.pages=50-63&rft.issn=2090-3170&rft.eissn=2090-3189&rft_id=info:doi/10.1155/2013/284036&rft_dat=%3Cgale_doaj_%3EA373578717%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a599t-f9f40c116231ca25d23c65fa92af1f1acd86fe4e39769ce2e60c5e82da5e786a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1540111378&rft_id=info:pmid/24324894&rft_galeid=A373578717&rft_airiti_id=P20151207002_201312_201708020006_201708020006_50_63&rfr_iscdi=true